We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Good to see Physiomics among the companies listed in the report
The DDR therapeutics market was estimated to be valued at US$5.9 billion in 2022 and is projected to reach US$10.4 billion by 2031 with a CAGR of 6.5%1. This is expected to be driven by an increase in the use of combination therapy for the treatment of drug-resistant cancers and the need for novel targeted medicines for cancer treatment. Most cancers rely on the DDR pathway to a greater extent than healthy cells.
Thanks NK
Pyc are at the forefront of huge change in drug approval amd testing using A.I and mathematics
They ar e due to hit £900k+revenues and a pipeline of £1.6mln (up 60% in 4mths )
PYC current valuation is ludicrous
Absolutely agree. The signs are all pointing towards an exciting upward movement. Bullish all the way
Https://marketresearchblog.org/2024/03/united-state-and-canada-biosimulation-industry/
Its on the cusp of breaking this and surpassing it.....BULLISH
Really wouldn't surprise me if news landed next week after a big week of conferences as well as a trading update due in May
Morning King
Yes, on many occasions last 10 days its been hard buying or huying more than a few £1000
Past two Fridays we have seen position taking with a little bit of volume….lets see if people will try get ahead of the curve today
There is also FA stock about - will move north on nothing, it takes out 1.50 then it’s a bit of blue sky to 2
Itsnpretty simple to see/check/test during the day
Yes
Laura, are you saying that all the 1.48 trades during the day were buys?
1.48p was the buy price at the time
Its a contra ,meaning net =zero
Two delayed trades gone through 9.20 am just popped up now each 201k volume
Not showing buy or sell.
Https://www.share-talk.com/traders-cafe-with-zak-mir-bulletin-board-heroes-tuesday-23rd-april-2024/
On the yearly chart....
SP seems to be holding the 200DMA....Good sign.
Thanks msuk
If people can invest rather than trade it will be ideal
Eg someone bought ladt thing on Friday and sold 1st thing Monday for a loss,yet 2 days later it orse 15% more ...silly
1.55 break will signify break of the 200 ema ,significant
https://invst.ly/14ikpb
This almost describes perfectly PYC target market
With the increasing investigation of DNA damage response / PARP inhibitors, alone or in combination with chemotherapy or immunotherapy, there is a need for minimally invasive, robust and repeatable DDR assays. All the development work continues to add to the menu of assays owned by ANGLE that we can offer to other customers."
The DDR therapeutics market was estimated to be valued at US$5.9 billion in 2022 and is projected to reach US$10.4 billion by 2031 with a CAGR of 6.5%1. This is expected to be driven by an increase in the use of combination therapy for the treatment of drug-resistant cancers and the need for novel targeted medicines for cancer treatment. Most cancers rely on the DDR pathway to a greater extent than healthy cells. Treating patients with a DDR inhibitor alongside another cancer drug helps to maximise DNA damage and selectively kill cancer cells. This provides a targeted approach to cancer treatment with the potential to improve patient outcomes across multiple tumour types.
Interesting developments at fellow bio tech AGL
Could well be PYC next to form this type of partnership? (Alongsode our work with merck)
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response ("DDR") assay for the detection of micronuclei in CTCs as a measure of DDR
Thanks Ralph
Link to Biotrinity.
https://twitter.com/hashtag/BioTrinity?src=hashtag_click
Buying has been good this week, finally is this great company going to be recognised in an AIM world where huge indebted comapnies ĺike BMN and Hzm are faltering